ArticleJournal of burn care & research : official publication of the American Burn Association2026
Reversibility of Immune Dysfunction Following Pediatric Thermal Injury.
Article in Journal of burn care & research : official publication of the American Burn Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pediatric thermal injury induces immune dysfunction, which is associated with adverse clinical outcomes (eg, nosocomial infections [NIs]). As such, it is crucial to identify those most at risk for developing NI and determine immunomodulating therapeutics to augment the immune response. Our hypothesis was that immune suppression after pediatric thermal injury is reversible ex-vivo using the immunomodulators recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF) and varlilumab (CD27-agonist). We enrolled 141 pediatric patients with acute thermal injuries from a single burn center. Blood samples were taken within the first week after injury to analyze immune function and ex-vivo reversibility. Pediatric patients with burn injuries who went on to develop an NI displayed a decrease in innate (ex-vivo lipopolysaccharide [LPS]-induced tumor necrosis factor alpha [TNFα] production capacity) and adaptive immune function (ex-vivo phytohemagglutinin [PHA]-induced interleukin [IL]-10 production capacity) compared to patients with burn injuries who recovered without infection. After correcting immune function measurements by the total number of cells, the ratio of LPS-induced TNFα/CD14+ monocytes decreased within the first 72 h for patients with burn injuries who developed an NI, whereas PHA-induced IL-10/CD4+ lymphocytes was significantly decreased at days 4-7. Samples co-incubated with GM-CSF significantly increased ex-vivo LPS-induced TNFα, while samples containing CD27 increased PHA-induced IL-10 production capacity, in the first 72 h, compared to samples that did not receive immunomodulators. The results of our study identified key markers to discover who is most at risk for developing NI, and provided early evidence of immunomodulators that may enhance immune function early after pediatric burn injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.